Join our daily newsletter At The Bell to receive exclusive market insights
- Immutep (IMM) publishes new “favourable” data from its first line non-small cell lung cancer (NSCLC) patients of its Phase II TACTI-002 trial
- The trial is evaluating eftilagimod alpha (efti) when used with collaboration partner MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients
- Key findings from the trial shows an overall response rate (ORR) of 38.6 per cent in the intent to treat (ITT) group and 42.7 per cent for evaluable patients by local read
- The company will host a global webcast to discuss the new data released in this trial which will include an analyst Q&A on June 7
- Shares in Immutep are trading flat at 43 cents at 10:51 am AEST
Immutep (IMM) published new “favourable” data from its first line non-small cell lung cancer (NSCLC) patients of its Phase II TACTI-002 trial.
The trial evaluated eftilagimod alpha (efti when used with collaboration partner MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients.
TACTI-002 Principal Investigator Dr Enriqueta Felip said it is very encouraging to see the combination of efti plus pembrolizumab showing favourable anti-tumour activity.
“These responses were deep and durable and there has also been a low patient discontinuation rate.
“I believe the combination of efti plus pembrolizumab warrants late stage clinical investigation.”
Key findings from the trial showed an overall response rate (ORR) of 38.6 per cent in the intent to treat (ITT) group and 42.7 per cent for evaluable patients by local read.
Overall, the combination showed favourable efficacy in first line NSCLC in the PD-L1 allcomer population and in all PD-L1 status groups, and with a low treatment discontinuation rate.
The company noted that data support continued late stage development in this indication.
CSO and CMO Dr Frederic Triebel calls the results encouraging, showing that efti may kick start an anti-tumour immune response even in patients with no or low PD-L1 expression.
“In addition, the combination of efti plus pembrolizumab has a safety profile consistent with that observed in previously reported studies for pembrolizumab monotherapy.
“We continue to believe that efti, with its unique mechanism of action, may ultimately provide a very meaningful benefit to diverse sets of cancer patients including those with more limited treatment options.”
The data was shown in an oral presentation at the American Society of Clinical Oncology’s (ASCO) 2022 annual meeting.
Further, the company will host a global webcast to discuss the new data released in this trial which will include an analyst Q&A on June 7 AEST.
Further results are expected to be reported from TACTI-002 in the second half of the year.
Shares in Immutep were trading flat at 43 cents at 10:51 am AEST.
